DDInter458 DDInter1379
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Escitalopram
Escitalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Palbociclib
Cyclosporine {u} (Compound) downregulates {v} (Gene) BACE2
BACE2 {u} (Gene) is downregulated by {v} (Compound) Escitalopram
Escitalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Palbociclib
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Simvastatin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palbociclib
Cyclosporine {u} (Compound) upregulates {v} (Gene) RRP12
RRP12 {u} (Gene) is downregulated by {v} (Compound) Escitalopram
Escitalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Palbociclib
Cyclosporine {u} (Compound) causes {v} (Side Effect) Dysmenorrhoea
Dysmenorrhoea {u} (Side Effect) is caused by {v} (Compound) Escitalopram
Escitalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Palbociclib
Cyclosporine {u} (Compound) upregulates {v} (Gene) RRP12
RRP12 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palbociclib
Cyclosporine {u} (Compound) causes {v} (Side Effect) Dysmenorrhoea
Dysmenorrhoea {u} (Side Effect) is caused by {v} (Compound) Oxcarbazepine
Oxcarbazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palbociclib
Cyclosporine {u} (Compound) upregulates {v} (Gene) RRP12
RRP12 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palbociclib
Cyclosporine {u} (Compound) causes {v} (Side Effect) Dysmenorrhoea
Dysmenorrhoea {u} (Side Effect) is caused by {v} (Compound) Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Palbociclib
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Amprenavir
Amprenavir {u} may lead to a major life threatening interaction when taken with {v} Palbociclib
Cyclosporine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Escitalopram (Compound) and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Cyclosporine (Compound) downregulates BACE2 (Gene) and BACE2 (Gene) is downregulated by Escitalopram (Compound) and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Cyclosporine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Simvastatin (Compound) and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Cyclosporine (Compound) upregulates RRP12 (Gene) and RRP12 (Gene) is downregulated by Escitalopram (Compound) and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Cyclosporine (Compound) causes Dysmenorrhoea (Side Effect) and Dysmenorrhoea (Side Effect) is caused by Escitalopram (Compound) and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Cyclosporine (Compound) upregulates RRP12 (Gene) and RRP12 (Gene) is downregulated by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Cyclosporine (Compound) causes Dysmenorrhoea (Side Effect) and Dysmenorrhoea (Side Effect) is caused by Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Cyclosporine (Compound) upregulates RRP12 (Gene) and RRP12 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Cyclosporine (Compound) causes Dysmenorrhoea (Side Effect) and Dysmenorrhoea (Side Effect) is caused by Clarithromycin (Compound) and Clarithromycin may lead to a major life threatening interaction when taken with Palbociclib
Cyclosporine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Amprenavir (Compound) and Amprenavir may lead to a major life threatening interaction when taken with Palbociclib